Harfst & Associates, Inc. Gilead Sciences, Inc. Transaction History

Harfst & Associates, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$63.47 - $69.35 $445,686 - $486,975	-7,022 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$60.0 - $68.46 $833,580 - $951,114	-13,893 Reduced 66.43%	7,022 $453,000
Q4 2020 Jan 25, 2021	BUY	$56.65 - $64.55 $304,777 - $347,279	5,380 Added 34.63%	20,915 $1.22 Million
Q3 2020 Nov 04, 2020	SELL	$62.1 - $78.08 $9,439 - $11,868	-152 Reduced 0.97%	15,535 $981,000
Q2 2020 Aug 07, 2020	BUY	$72.34 - $84.0 $7,451 - $8,652	103 Added 0.66%	15,687 $1.21 Million
Q1 2020 May 05, 2020	BUY	$62.63 - $80.22 $735,526 - $942,103	11,744 Added 305.83%	15,584 $1.17 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $3,450 - $3,795	-56 Reduced 1.44%	3,840 $249,000
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $243,538 - $268,824	3,896 New	3,896 $246,000
Q3 2017 Nov 07, 2017	SELL	$72.11 - $85.47 $27,690 - $32,820	-384 Closed	0 $0
Q2 2017 Aug 11, 2017	BUY	N/A	384	384 $27,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Harfst & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Harfst & Associates, Inc. with notifications on news.